Batanopride

Batanopride

Batanopride
Systematic (IUPAC) name
4-amino-5-chloro-N-(2-diethylaminoethyl)-2-(3-oxobutan-2-yloxy)benzamide
Clinical data
Legal status
  • Uncontrolled
Routes Oral
Identifiers
CAS number  N
ATC code None
PubChem
ChemSpider  YesY
UNII  YesY
ChEMBL  YesY
Chemical data
Formula C17H26ClN3O3 
Mol. mass 355.860 g/mol
 N   

Batanopride (BMY-25,801) is an antiemetic drug of the benzamide class which acts as a selective 5-HT3 receptor antagonist.[1] It was trialled to reduce nausea during cancer chemotherapy, but was never approved for medical use due to dose-limiting side effects including hypotension and long QT syndrome.[2]

References

  1. ^ Gylys JA, Wright RN, Nicolosi WD, Buyniski JP, Crenshaw RR. BMY-25801, an antiemetic agent free of D2-dopamine receptor antagonist properties. Journal of Pharmacology and Experimental Therapeutics. 1988 Mar;244(3):830-7. PMID 2978041
  2. ^ Fleming GF, Vokes EE, McEvilly JM, Janisch L, Francher D, Smaldone L. Double-blind, randomized crossover study of metoclopramide and batanopride for prevention of cisplatin-induced emesis. Cancer Chemotherapy and Pharmacology. 1991;28(3):226-7. PMID 1855280